更新于：2024-06-20
Asparagine
门冬酰胺
更新于：2024-06-20
概要
基本信息
原研机构 |
在研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期- |
最高研发阶段(中国)批准上市 |
特殊审评- |
结构
分子式C4H8N2O3 |
InChIKeyDCXYFEDJOCDNAF-REOHCLBHSA-N |
CAS号70-47-3 |
关联
1
项与 门冬酰胺 相关的临床试验A prospective, multicenter, single arm, open label study of PD1 antibody in the treatment of Epstein Barr virus DNA positive NK / T cell lymphoma after asparagine containing chemotherapy
100 项与 门冬酰胺 相关的临床结果
登录后查看更多信息
100 项与 门冬酰胺 相关的转化医学
登录后查看更多信息
100 项与 门冬酰胺 相关的专利（医药）
登录后查看更多信息
821
项与 门冬酰胺 相关的文献（医药）2024-03-01World journal of microbiology & biotechnology
Application of sequential design for enhanced l-asparaginase synthesis from Ganoderma australe GPC191
Article
作者: Chakraborty, Meghna ; Shivakumar, Srividya
With an increasing demand for L-asparaginase in pharmaceutical and food sectors for its cytostatic and acrylamide-reducing qualities, there's a need to discover novel, highly productive enzyme sources with improved pharmacokinetic profiles. Keeping this in mind, the present study aimed at maximizing the potential of Ganoderma australe GPC191 to produce L-asparaginase by fermentation medium optimization using statistical validation. Of the 11 physicochemical parameters evaluated under submerged fermentation conditions through one-factor-at-a-time approach and Plackett-Burman design, only four parameters (inoculum load, L-asparagine, soybean meal, and initial pH) influenced L-asparaginase production, significantly (p < 0.001). The optimal levels and interaction effects of these on the overall production were further evaluated by the central composite rotatable design of response surface methodology. Post-optimization, 27.34 U/mL was predicted as the maximum activity at pH 7 with 5n inoculum load and 15 g/L each of L-asparagine and soybean meal. Experimental validation yielded an activity of 28.52 U/mL, indicating an overall 18.17-fold increase from the unoptimized stage. To our knowledge, this is the first report signifying the L-asparaginase production aptitude of G. australe with sequential statistical validation using agricultural waste, which can serve as a model to enhance its yields, offering a sustainable and cost-effective solution for industrial application.
2024-01-14The British journal of nutrition
Effects of partial replacement of red and processed meat with non-soya legumes on bone and mineral metabolism and amino acid intakes in BeanMan randomised clinical trial
Article
作者: Karhu, Piia ; Lehtovirta, Mikko ; Kaartinen, Niina E ; Männistö, Satu ; Itkonen, Suvi T ; Pajari, Anne-Maria ; Päivärinta, Essi ; Pellinen, Tiina
Abstract:
The transition towards more plant-based diets may pose risks for bone health such as low vitamin D and Ca intakes. Findings for the contribution of animal and plant proteins and their amino acids (AA) to bone health are contradictory. This 6-week clinical trial aimed to investigate whether partial replacement of red and processed meat (RPM) with non-soya legumes affects AA intakes and bone turnover and mineral metabolism in 102 healthy 20–65-year-old men. Participants were randomly assigned to diet groups controlled for RPM and legume intake (designed total protein intake (TPI) 18 E%): the meat group consumed 760 g RPM per week (25 % TPI) and the legume group consumed non-soya legume-based products (20 % TPI) and 200 g RPM per week, the upper limit of the Planetary Health Diet (5 % TPI). No differences in bone (bone-specific alkaline phosphatase; tartrate-resistant acid phosphatase 5b) or mineral metabolism (25-hydroxyvitamin D; parathyroid hormone; fibroblast growth factor 23; phosphate and Ca) markers or Ca and vitamin D intakes were observed between the groups (P > 0·05). Methionine and histidine intakes were higher in the meat group (P ≤ 0·042), whereas the legume group had higher intakes of arginine, asparagine and phenylalanine (P ≤ 0·013). Mean essential AA intakes in both groups met the requirements. Increasing the proportion of non-soya legumes by reducing the amount of RPM in the diet for 6 weeks did not compromise bone turnover and provided on average adequate amounts of AA in healthy men, indicating that this ecologically sustainable dietary change is safe and relatively easy to implement.
2024-01-14The British journal of nutrition
The influence of substituting dietary peptide-bound with free amino acids on nitrogen metabolism and acid–base balance of broiler chickens depends on asparagine and glutamine supply
Article
作者: Siegert, Wolfgang ; Kenéz, Ákos ; Rodehutscord, Markus ; Ibrahim, Ahmad
Abstract:
Reducing dietary crude protein (CP) concentration while maintaining adequate amino acid (AA) supply by free AA inclusion can contribute to attenuate the negative environmental effects of animal farming. This study investigated upper limits of dietary free AA inclusions without undesirable effects including the dependence on asparagine (Asn) and glutamine (Gln) supply. Ten broilers were allocated to sixty-three metabolism units each and offered nine experimental diets from day (d) 7–21 (n 7). One diet (167 g CP/kg) contained 80 g soya protein isolate (SPI)/kg. In the other diets, 25, 50, 75 and 100 % of the digestible AA from SPI were substituted with free AA. Digestible Asn+aspartic acid (Asp) and Gln+glutamic acid (Glu) were substituted with Asp/Glu or 50/50 mixes of Asp/Asn and Glu/Gln, respectively. Total excreta were collected from d 11–14 and from d 18–21. Growth and nitrogen accretion were unaffected by 25 and 50 % substitution without and with free Asn/Gln, respectively, but decreased at higher substitution (P ≤ 0·024). Circulating concentrations of Asp, Glu and Gln were unaffected by treatment, while Asn decreased at substitution higher than 50 % when Asn/Gln were not provided (P ≤ 0·005). Blood gas analysis on d 21 indicated a compensated metabolic acidosis at substitution higher than 50 and 75 % without and with free Asn/Gln, respectively (P ≤ 0·017). Results suggest that adding Asn/Gln increased an upper limit for proportion of dietary free AA from 10 to 19 % of dietary CP and enabled higher free AA inclusion without affecting the acid–base balance.
100 项与 门冬酰胺 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 乳腺疾病 | 中国 | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 30 | 衊壓顧構鹽簾糧鏇願鑰(壓夢衊膚願襯衊襯鏇鏇) = 鹹選醖齋糧遞繭鏇繭餘 鏇餘衊廠選鹽願齋顧醖 (構憲遞衊衊觸艱齋鑰繭 ) 更多 | - | 2022-06-02 | |||
(HyperCVAD) | 衊壓顧構鹽簾糧鏇願鑰(壓夢衊膚願襯衊襯鏇鏇) = 網簾醖觸簾襯醖顧網鬱 鏇餘衊廠選鹽願齋顧醖 (構憲遞衊衊觸艱齋鑰繭 ) 更多 | ||||||
N/A | - | (AD brains) | 淵壓繭鑰鑰獵觸鏇積齋(鑰構廠鏇鬱製遞鏇壓廠) = 鑰鏇願鑰顧襯夢築獵選 獵醖窪憲願積遞衊鹹鏇 (膚餘網鬱顧夢憲淵糧願 ) | - | 2011-07-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用